Quick Answer
CORCEPT THERAPEUTICS INC reported Total Revenue of $761.41 million for fiscal year 2025.
CORCEPT THERAPEUTICS INC — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $761.41M +12.8% |
$675.04M +39.9% |
$482.38M +20.0% |
$401.86M +9.8% |
$365.98M +3.4% |
$353.87M +15.5% |
| Revenue (ASC 606) | $761.41M +12.8% |
$675.04M +39.9% |
$482.38M +20.0% |
$401.86M +9.8% |
$365.98M +3.4% |
$353.87M +15.5% |
| Net Income | $99.65M -29.4% |
$141.21M +33.0% |
$106.14M +4.7% |
$101.42M -9.9% |
$112.51M +6.1% |
$106.01M +12.6% |
| Diluted EPS | $0.82 -33.3% |
$1.23 +30.9% |
$0.94 +8.0% |
$0.87 -2.2% |
$0.89 +4.7% |
$0.85 +10.4% |
| Total Assets | $836.65M -0.5% |
$840.55M +35.2% |
$621.52M +6.5% |
$583.43M +37.7% |
$423.76M -25.9% |
$571.73M +38.7% |
| Cash and Equivalents | $120.50M -5.6% |
$127.67M -5.8% |
$135.55M +104.4% |
$66.33M -14.5% |
$77.62M +1.9% |
$76.19M +143.7% |
| Long-Term Debt | — | — | — | — | — | — |
| Stockholders Equity | $647.80M -4.7% |
$679.59M +34.1% |
$506.70M +1.0% |
$501.84M +33.5% |
$375.81M -28.2% |
$523.34M +41.0% |
| R&D Expense | $254.91M +3.2% |
$246.89M +33.9% |
$184.35M +40.7% |
$130.99M +15.0% |
$113.86M -0.8% |
$114.76M +28.9% |
| Operating Income | $44.80M -67.3% |
$136.95M +27.7% |
$107.28M -4.8% |
$112.63M -9.5% |
$124.48M -2.9% |
$128.20M +14.9% |
| Shares Outstanding | 105.97M +0.8% |
105.11M +1.7% |
103.41M -4.1% |
107.83M +1.8% |
105.94M -9.2% |
116.73M +1.9% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $207.64M | +13.7% | +6.8% |
| Revenue (ASC 606) | September 30, 2025 | $207.64M | +13.7% | +6.8% |
| Net Income | September 30, 2025 | $19.67M | -58.3% | -44.0% |
| Diluted EPS | September 30, 2025 | $0.16 | -61.0% | -44.8% |
| Total Assets | September 30, 2025 | $823.61M | +5.0% | +2.7% |
| Cash and Equivalents | September 30, 2025 | $125.14M | -8.9% | +21.8% |
| Long-Term Debt | September 30, 2016 | $0.00 | -100.0% | -100.0% |
| Stockholders Equity | September 30, 2025 | $631.90M | -1.1% | -0.6% |
| R&D Expense | September 30, 2025 | $68.85M | +16.0% | +13.8% |
| Operating Income | September 30, 2025 | $10.22M | -78.1% | -61.7% |
| Shares Outstanding | September 30, 2017 | 114.08M | +2.9% | +0.6% |
- CORCEPT THERAPEUTICS INC reported Total Revenue of $761.41 million for fiscal year 2025.
- CORCEPT THERAPEUTICS INC showed an increase of +12.8% in Total Revenue compared to the prior fiscal year.
- CORCEPT THERAPEUTICS INC reported Revenue (ASC 606) of $761.41 million for fiscal year 2025.
- CORCEPT THERAPEUTICS INC showed an increase of +12.8% in Revenue (ASC 606) compared to the prior fiscal year.
- CORCEPT THERAPEUTICS INC reported Net Income of $99.65 million for fiscal year 2025.
- CORCEPT THERAPEUTICS INC showed a decrease of -29.4% in Net Income compared to the prior fiscal year.
- CORCEPT THERAPEUTICS INC reported Diluted EPS of $0.82 per share for fiscal year 2025.
- CORCEPT THERAPEUTICS INC showed a decrease of -33.3% in Diluted EPS compared to the prior fiscal year.
- CORCEPT THERAPEUTICS INC reported Total Assets of $836.65 million for fiscal year 2025.
- CORCEPT THERAPEUTICS INC showed a decrease of -0.5% in Total Assets compared to the prior fiscal year.
- CORCEPT THERAPEUTICS INC reported Cash and Equivalents of $120.50 million for fiscal year 2025.
- CORCEPT THERAPEUTICS INC showed a decrease of -5.6% in Cash and Equivalents compared to the prior fiscal year.
- CORCEPT THERAPEUTICS INC reported Long-Term Debt of $0.00 for fiscal year 2016.
- CORCEPT THERAPEUTICS INC showed a decrease of -100.0% in Long-Term Debt compared to the prior fiscal year.
- CORCEPT THERAPEUTICS INC reported Stockholders Equity of $647.80 million for fiscal year 2025.
- CORCEPT THERAPEUTICS INC showed a decrease of -4.7% in Stockholders Equity compared to the prior fiscal year.
- CORCEPT THERAPEUTICS INC reported R&D Expense of $254.91 million for fiscal year 2025.
- CORCEPT THERAPEUTICS INC showed an increase of +3.2% in R&D Expense compared to the prior fiscal year.
- CORCEPT THERAPEUTICS INC reported Operating Income of $44.80 million for fiscal year 2025.
- CORCEPT THERAPEUTICS INC showed a decrease of -67.3% in Operating Income compared to the prior fiscal year.
- CORCEPT THERAPEUTICS INC reported Shares Outstanding of 105.97 million shares for fiscal year 2025.
- CORCEPT THERAPEUTICS INC showed an increase of +0.8% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: